Texas Roadhouse earnings missed by $0.05, revenue topped estimates
TORONTO - Lifeist Wellness Inc. (TSX.V:LFST; OTCQB:LFSWF), a wellness company with a market capitalization of $1.64 billion and revenue growth of 16.31% in the last twelve months, announced Thursday that its subsidiary Mikra Cellular Sciences has formed strategic partnerships with fitness platforms ASICS Runkeeper app and Race Roster.
The collaboration, signed on May 26, aims to connect Mikra’s performance-focused supplements directly with active athletes seeking mental clarity and enhanced performance. In June, Mikra launched exclusive fitness challenges within the Runkeeper app to engage the platform’s U.S. community of runners. According to InvestingPro analysis, while the company’s stock is currently trading near its 52-week low, analysts expect net income growth this year, suggesting potential upside from these strategic initiatives.
"ASICS’ position as among the most trusted global running brands makes it an ideal partner for Mikra," said Andrea Judge, CEO of Lifeist, according to the company’s press release.
The partnership with Race Roster enables Mikra to integrate brand messaging and product promotions during event registrations. The company reported that its first event generated 39,000 new users and more than 7,500 entries.
Lifeist describes the arrangement as a strategy to accelerate customer acquisition while reducing traditional marketing costs associated with wellness advertising.
Mikra Cellular Sciences develops supplements focused on cognitive and emotional resilience, aligning with what the company calls its "Mind-First Movement" philosophy.
The information in this article is based on a press release from Lifeist Wellness Inc.
In other recent news, LifeStance Health Group reported its Q1 2025 earnings, marking a significant milestone with a positive net income for the first time. The company also saw a notable increase in both revenue and adjusted EBITDA, which has been well-received by investors. UBS analyst Kevin Caliendo upgraded LifeStance Health’s stock rating to "Buy," setting a price target of $8.50, citing the company’s strong growth potential despite previous stock weaknesses. This upgrade follows a robust first quarter that surpassed expectations, even amidst a conservative outlook for the future.
In governance updates, LifeStance Health held its annual stockholder meeting, where Teresa DeLuca, Katherine Wood, and Eric Palmer were elected to the Board of Directors for three-year terms. Additionally, the company announced the appointment of Vaughn Paunovich as the new Chief Technology Officer, starting June 9, 2025. Paunovich brings over two decades of experience in healthcare technology, with previous roles at Amwell and UnitedHealth Group. His leadership is anticipated to advance LifeStance Health’s technology strategy, enhancing the experience for both patients and providers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.